APA (7th ed.) Citation

Shah A, Tosh JC, Ambavane A, Nikolaou A, Hogea C, Samyshkin Y, . . . Wang F. (2021). Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. Dove Medical Press.

Chicago Style (17th ed.) Citation

Shah A, Tosh JC, Ambavane A, Nikolaou A, Hogea C, Samyshkin Y, Gorsh B, Maiese EM, and Wang F. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. Dove Medical Press, 2021.

MLA (9th ed.) Citation

Shah A, et al. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. Dove Medical Press, 2021.